xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT05998408</url>
    </required_header>
    <id_info>
      <org_study_id>10001667</org_study_id>
      <secondary_id>001667-H</secondary_id>
      <nct_id>NCT05998408</nct_id>
    </id_info>
    <brief_title>JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure</brief_title>
    <official_title>A Phase I/II Study of the JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
        <agency_class>NIH</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>National Institutes of Health Clinical Center (CC)</source>
    <oversight_info>
      <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        Background:&#xD;
  &#xD;
        Immune bone marrow failure is a condition that occurs when a person s immune system attacks&#xD;
        the cells of the bone marrow. This can lead to diseases including different types of anemias&#xD;
        and blood cancers. Some of these diseases can be deadly. Better treatments are needed.&#xD;
  &#xD;
        Objective:&#xD;
  &#xD;
        To test a drug (ruxolitinib) in people with different types of immune bone marrow failure.&#xD;
  &#xD;
        Eligibility:&#xD;
  &#xD;
        Adults aged 18 and older with an immune bone marrow failure.&#xD;
  &#xD;
        Design:&#xD;
  &#xD;
        Participants will be screened. They will have a physical exam. They will give samples of&#xD;
        blood and saliva. They will have a bone marrow biopsy: A large needle will be inserted into a&#xD;
        small cut to remove a sample of the soft tissue inside the bone. Some participants may have a&#xD;
        skin biopsy: A small piece of skin will be removed. Some may have a computed tomography (CT)&#xD;
        scan: They will lie on a table that slides into a donut-shaped machine that uses X-rays to&#xD;
        make pictures of the inside of the body.&#xD;
  &#xD;
        Ruxolitinib is a tablet taken by mouth. Participants will take the drug twice a day for up to&#xD;
        6 months.&#xD;
  &#xD;
        Participants will have blood tests every week while they are taking the drug. These tests can&#xD;
        be done by the participant s own physician and the results sent to the researchers.&#xD;
  &#xD;
        Participants will have clinic visits after taking the drug for 3 months and 6 months and then&#xD;
        after 1, 2, and 3 years. The blood tests and bone marrow biopsy will be repeated.&#xD;
  &#xD;
        Participants who improve while taking the drugs may go on to an extension phase of the study.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        Study description:&#xD;
  &#xD;
        This is a prospective, non-randomized, phase I/II study in which participants with&#xD;
        relapsed/refractory immune marrow failure (severe aplastic anemia, moderate aplastic anemia,&#xD;
        single lineage cytopenias, T-LGL, and hypoplastic MDS) will be treated with the JAK1/2&#xD;
        inhibitor ruxolitinib. Our hypothesis is that JAK1/2 inhibition with ruxolitinib will result&#xD;
        in hematologic improvement in participants with immune marrow failure.&#xD;
  &#xD;
        Objectives:&#xD;
  &#xD;
        The primary objectives are to assess safety and efficacy of the JAK1/2 inhibitor ruxolitinib&#xD;
        in immune marrow failure.&#xD;
  &#xD;
        The secondary objectives are to assess early and long-term hematologic response, depth of&#xD;
        response, development of transfusion independence, rate of relapse, rate of clonal evolution&#xD;
        to myeloid malignancy and Paroxysmal Nocturnal Hemoglobinuria (PNH), 3-year overall survival,&#xD;
        response after re-initiation of therapy in relapsed participants, maximum tolerated dose.&#xD;
  &#xD;
        Endpoints:&#xD;
  &#xD;
        The primary endpoints are: (a) the primary safety endpoint will be number of participants who&#xD;
        complete a full course of ruxolitinib without cessation required by hematologic toxicity in&#xD;
        the 6 months following treatment initiation; (b) The primary efficacy endpoint is overall&#xD;
        response (OR) rate by 6 months.&#xD;
  &#xD;
        The secondary endpoints are time to OR, OR at 3 months, development of transfusion&#xD;
        independence at 3 and 6 months, type of response at 3 and 6 months, rate of relapse up to 3&#xD;
        years, rate of clonal evolution up to 3 years, 3-year overall survival (OS), and number of&#xD;
        participants tolerating maximum ruxolitinib dose.&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Not yet recruiting</overall_status>
    <start_date type="Anticipated">October 3, 2023</start_date>
    <completion_date type="Anticipated">June 3, 2032</completion_date>
    <primary_completion_date type="Anticipated">June 3, 2030</primary_completion_date>
    <phase>Phase 1/Phase 2</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>Non-Randomized</allocation>
      <intervention_model>Single Group Assignment</intervention_model>
      <primary_purpose>Treatment</primary_purpose>
      <masking>None (Open Label)</masking>
    </study_design_info>
    <primary_outcome>
      <measure>The number of patients who complete a full course of ruxolitinib without cessation is required by hematologic toxicity.</measure>
      <time_frame>6 months</time_frame>
      <description>The primary safety endpoint will be the number of patients who complete a full course of ruxolitinib without cessation required by hematologic toxicity in the 6 months following treatment initiation.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Overall Response Rate. Patients who develop a Complete response at 3 months and stop the drug will also be deemed responders even if they subsequently relapse.</measure>
      <time_frame>6 months</time_frame>
      <description>The primary efficacy endpoint is the OR rate by 6 months. Patients who develop CR at 3 months and stop the drug will also be deemed responders even if they subsequently relapse.</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>Hematological response</measure>
      <time_frame>3, 12 months, and yearly thereafter</time_frame>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Depth of response</measure>
      <time_frame>3, 6 months</time_frame>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Rate of clonal evolution</measure>
      <time_frame>Variable</time_frame>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Rate of relapse</measure>
      <time_frame>Variable</time_frame>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Time to transfusion independence</measure>
      <time_frame>Variable</time_frame>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Overall survival</measure>
      <time_frame>Variable</time_frame>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Hematological response of relapse subjects that re-start treatment</measure>
      <time_frame>Variable</time_frame>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Percent of patients tolerating 20 mg ruxolitinib BID.</measure>
      <time_frame>Variable</time_frame>
    </secondary_outcome>
    <number_of_arms>5</number_of_arms>
    <enrollment type="Anticipated">145</enrollment>
    <condition>Severe Aplastic Anemia</condition>
    <condition>Single Lineage Cytopenias, T-LGL</condition>
    <condition>Hypoplastic MDS</condition>
    <arm_group>
      <arm_group_label>Subjects with hypoplastic MDS</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Subjects are defined as patients with a diagnosis of hMDS clinically confirmed by a licensed physician or an advanced practitioner who meets the inclusion and exclusion criteria and can provide informed consent.</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Subjects with MAA</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Subjects are defined as patients with a diagnosis of MAA clinically confirmed by a licensed physician or an advanced practitioner who meets the inclusion andexclusion criteria and can provide informed consent.</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Subjects with PRCA</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Subjects are defined as patients with a diagnosis of PRCA clinically confirmed by a licensed physician or advanced practitioners who meet the inclusion and exclusion criteria and can provide informed consent.</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Subjects with SAA</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Subjects are defined as patients with a diagnosis of SAA clinically confirmed by a licensed physician oran advanced practitioner who meets the inclusion andexclusion criteria and can provide informed consent.</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Subjects with TLGL</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Subjects are defined as patients with a diagnosis of TLGL clinically confirmed by a licensed physician or advanced practitioner who meets the inclusion and exclusion criteria and can provide informed consent.</description>
    </arm_group>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>Ruxolitinib</intervention_name>
      <description>Subjects will be instructed to take ruxolitinib at up to 20mg (total) BID for up to 6 months (with or without food)</description>
      <arm_group_label>Subjects with MAA</arm_group_label>
      <arm_group_label>Subjects with PRCA</arm_group_label>
      <arm_group_label>Subjects with SAA</arm_group_label>
      <arm_group_label>Subjects with TLGL</arm_group_label>
      <arm_group_label>Subjects with hypoplastic MDS</arm_group_label>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          -  INCLUSION/EXCLUSION CRITERIA:&#xD;
  &#xD;
          Participants of both sexes will be considered for inclusion in this study. There will be no&#xD;
          racial, ethnic, or gender discrimination. To be eligible to participate in the treatment&#xD;
          portion of this study, an individual must meet all of the following inclusion criteria and&#xD;
          none of the following exclusion criteria:&#xD;
  &#xD;
          INCLUSION CRITERIA:&#xD;
  &#xD;
          ALL COHORTS:&#xD;
  &#xD;
            -  Ability of the participant or legally authorized representative (LAR) to understand&#xD;
               and be willing to sign a written informed consent document&#xD;
  &#xD;
            -  Age 18 or older&#xD;
  &#xD;
            -  For females of childbearing potential, stated willingness to use an accepted method of&#xD;
               contraception for the duration of the study. Accepted methods of contraception are:&#xD;
  &#xD;
                 -  Total abstinence&#xD;
  &#xD;
                 -  Use of an implanted or intrauterine hormonal device for at least 30 consecutive&#xD;
                    days before study drug administration&#xD;
  &#xD;
                 -  Use of oral, patch or injectable contraceptives or a vaginal hormonal device for&#xD;
                    at least 30 consecutive days before study drug infusion&#xD;
  &#xD;
                 -  Use of a non-hormonal intrauterine device for at least 30 consecutive days before&#xD;
                    study drug administration&#xD;
  &#xD;
                 -  Two barrier methods such as a diaphragm with spermicide or a condom with&#xD;
                    spermicide&#xD;
  &#xD;
            -  For sexually active males with a female partner of childbearing potential, stated&#xD;
               willingness to agree to use a condom with spermicide for the duration of the study.&#xD;
  &#xD;
            -  Diagnosis of immune bone marrow failure (see specific cohort)&#xD;
  &#xD;
          COHORT 1: RELAPSED/REFRACTORY SAA:&#xD;
  &#xD;
          Meet all 3 criteria below:&#xD;
  &#xD;
          Severe aplastic anemia:&#xD;
  &#xD;
          -Bone marrow cellularity &lt;30% excluding lymphocytes&#xD;
  &#xD;
          AND&#xD;
  &#xD;
          At least two of the following:&#xD;
  &#xD;
            -  Absolute neutrophil count &lt; 0.5 x 10^9/L&#xD;
  &#xD;
            -  Platelet count &lt; 20 x 10^9/L&#xD;
  &#xD;
            -  Absolute Reticulocyte count &lt; 60 x 10^9/L&#xD;
  &#xD;
                 -  Relapsed or refractory disease as evidenced by a course of at least 1 prior&#xD;
                    therapy.&#xD;
  &#xD;
                 -  Not suitable for transplant due to age, co-morbidities, lack of suitable donor,&#xD;
                    or participant choice.&#xD;
  &#xD;
          COHORT 2: RELAPSED/REFRACTORY MODERATE AA:&#xD;
  &#xD;
          Moderate AA:&#xD;
  &#xD;
            -  Aplastic anemia (hypocellular bone marrow for age) with no evidence for other disease&#xD;
               processes causing marrow failure, and depression of at least two out of three blood&#xD;
               counts below the normal values but not fulfilling the criteria for SAA:&#xD;
  &#xD;
                 -  Absolute neutrophil count &lt;= l.2 x 10^9/L&#xD;
  &#xD;
                 -  Platelet count &lt;= 70 x 10^9/L&#xD;
  &#xD;
                 -  Anemia with hemoglobin &lt;= 9 g/dL and absolute reticulocyte count &lt; 60 x 10^9/L or&#xD;
                    transfusion dependence&#xD;
  &#xD;
            -  Relapsed or refractory disease as evidenced by a course of at least 1 prior therapy.&#xD;
  &#xD;
          COHORT 3: RELAPSED/REFRACTORY UNILINEAGE BONE MARROW FAILURE DISORDERS:&#xD;
  &#xD;
          Cytopenia in lineage as below:&#xD;
  &#xD;
          -Erythroid lineage: Hemoglobin &lt;= 9 g/dL and reticulocyte count &lt; 60 x 10^9/L or red cell&#xD;
          transfusion dependence and hypocellular bone marrow for age with absent or reduced red cell&#xD;
          precursors&#xD;
  &#xD;
          OR&#xD;
  &#xD;
          Platelet lineage: Thrombocytopenia &lt;= 30 x 10^9/L or platelet transfusion dependence and&#xD;
          hypocellular bone marrow for age with absent or reduced megakaryocytes&#xD;
  &#xD;
          OR&#xD;
  &#xD;
          Granulocyte lineage: Neutropenia &lt;= 0.5 x 10^9/L and hypocellular bone marrow for age with&#xD;
          absent or reduced granulopoiesis&#xD;
  &#xD;
            -  No evidence of viral or drug suppression of the marrow, T-LGL, dysplasia, or&#xD;
               underproduction anemias secondary to B12, folate, iron or other reversible causes.&#xD;
  &#xD;
            -  Relapsed or refractory disease as evidenced by a course of at least 1 prior therapy.&#xD;
  &#xD;
          COHORT 4: RELAPSED/REFRACTORY T-LGL WITH CYTOPENIAS:&#xD;
  &#xD;
            -  Clinical history supportive of the diagnosis of T-LGL leukemia (i.e., a history of&#xD;
               cytopenias with peripheral blood morphologic evidence of LGLs).&#xD;
  &#xD;
            -  Immunophenotypic studies of peripheral blood showing an increased population of T-LGLs&#xD;
               (suggested by staining with CD3+, CD8+ and CD16+ or CD57+) or gamma-delta T cells.&#xD;
  &#xD;
            -  Restricted or clonal rearrangement of the T-cell receptor by PCR&#xD;
  &#xD;
          AND cytopenia as follows:&#xD;
  &#xD;
          Severe neutropenia (&lt; 0.5 x 10^9/L);&#xD;
  &#xD;
          OR&#xD;
  &#xD;
          Severe thrombocytopenia (&lt;= 20 x 10^9/L), or moderate thrombocytopenia (&lt;= 50 x 10^9/L)&#xD;
          with active bleeding;&#xD;
  &#xD;
          OR&#xD;
  &#xD;
          Symptomatic anemia with a hemoglobin &lt;= 9 g/dL or red blood cell transfusion dependence&#xD;
  &#xD;
          -Relapsed or refractory disease as evidenced by a course of at least 1 prior therapy.&#xD;
  &#xD;
          COHORT 5: HYPOPLASTIC MDS:&#xD;
  &#xD;
          -A diagnosis of hypoplastic MDS by WHO 2016, WHO 2022, or ICC criteria with significant&#xD;
          cytopenias defined as:&#xD;
  &#xD;
          Bone marrow hypocellular for age&#xD;
  &#xD;
          AND&#xD;
  &#xD;
          Either morphologic dysplasia or cytogenetic abnormality&#xD;
  &#xD;
          AND&#xD;
  &#xD;
          At least one of the following:&#xD;
  &#xD;
            -  Neutropenia: Absolute neutrophil count &lt; 0.5 x 10^9/L&#xD;
  &#xD;
            -  Thrombocytopenia: Platelet count &lt; 30 x 10^9/L or platelet transfusion dependence&#xD;
  &#xD;
            -  Anemia: Hemoglobin &lt; 9g/dL or red cell transfusion-dependence or absolute reticulocyte&#xD;
               count &lt;60 x 10^9/L&#xD;
  &#xD;
                 -  Relapsed or refractory disease as evidenced by a course of at least 1 prior&#xD;
                    therapy&#xD;
  &#xD;
          EXCLUSION CRITERIA:&#xD;
  &#xD;
          An individual who meets any of the following criteria will be excluded from participation&#xD;
          in this study:&#xD;
  &#xD;
            -  Known diagnosis or high suspicion of Fanconi anemia or other constitutional marrow&#xD;
               failure syndrome&#xD;
  &#xD;
            -  Evidence of a clonal disorder with poor risk cytogenetics per R-IPSS criteria&#xD;
               involving chromosome 7 (-7del/-7), chromosome 3 (inv 3/del3/t(3)) or three or more&#xD;
               chromosomal abnormalities (complex).&#xD;
  &#xD;
            -  MDS with EB-1, EB-2, AML, chronic myelomonocytic leukemia (CMML), MDS/MPN.&#xD;
  &#xD;
            -  For MDS: Has received erythropoiesis-stimulating agent (ESA), hypomethylating agent,&#xD;
               chemotherapy, or immunomodulatory therapy within 8 weeks prior to study entry.&#xD;
  &#xD;
            -  History of progressive multifocal leuko-encephalopathy (PML)&#xD;
  &#xD;
            -  Infection not adequately responding to appropriate therapy&#xD;
  &#xD;
            -  Participants with untreated or poorly controlled HIV, Hepatitis B or C&#xD;
  &#xD;
            -  Participants with cancer who are on active chemotherapeutic treatment&#xD;
  &#xD;
            -  Presence of severely impaired renal function defined by CrCl (as calculated by eGFR)&#xD;
               less than 15 mL/min not requiring renal dialysis&#xD;
  &#xD;
            -  Current pregnancy, or unwillingness to take oral contraceptives or use a barrier&#xD;
               method of birth control or practice abstinence to refrain from pregnancy if of&#xD;
               childbearing potential during this study&#xD;
  &#xD;
            -  Moribund status or concurrent hepatic, renal, cardiac, neurologic, pulmonary,&#xD;
               infectious, or metabolic disease of such severity that it would preclude the&#xD;
               participant s ability to tolerate protocol therapy, or that death within 7-10 days is&#xD;
               likely&#xD;
  &#xD;
            -  Inability to understand the investigational nature of the study or to give informed&#xD;
               consent or does not have a legally authorized representative or surrogate that can&#xD;
               provide informed consent&#xD;
  &#xD;
            -  Hypersensitivity to ruxolitinib or its components&#xD;
  &#xD;
            -  Inability to swallow pills&#xD;
  &#xD;
            -  Currently breastfeeding&#xD;
  &#xD;
            -  Active non-melanoma skin cancer&#xD;
  &#xD;
            -  Acute thrombosis (myocardial infarction, ischemic heart disease requiring stents,&#xD;
               stroke, pulmonary embolism, or deep venous thrombosis) within the last 6 months&#xD;
  &#xD;
            -  Patients with a PNH clone &gt;50% who are not taking anticoagulation or anticomplement&#xD;
               therapy&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>99 Years</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>Emma M Groarke, M.D.</last_name>
      <role>Principal Investigator</role>
      <affiliation>National Heart, Lung, and Blood Institute (NHLBI)</affiliation>
    </overall_official>
    <overall_contact>
      <last_name>Ivana Darden, R.N.</last_name>
      <phone>(301) 827-2988</phone>
      <email>ivana.darden@nih.gov</email>
    </overall_contact>
    <overall_contact_backup>
      <last_name>Emma M Groarke, M.D.</last_name>
      <phone>(301) 496-5093</phone>
      <email>emma.groarke@nih.gov</email>
    </overall_contact_backup>
    <location>
      <facility>
        <name>National Institutes of Health Clinical Center</name>
        <address>
          <city>Bethesda</city>
          <state>Maryland</state>
          <zip>20892</zip>
          <country>United States</country>
        </address>
      </facility>
      <contact>
        <last_name>NIH Clinical Center Office of Patient Recruitment (OPR)</last_name>
        <phone>800-411-1222</phone>
        <phone_ext>TTY dial 711</phone_ext>
        <email>ccopr@nih.gov</email>
      </contact>
    </location>
    <location_countries>
      <country>United States</country>
    </location_countries>
    <link>
      <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_001667-H.html</url>
      <description>NIH Clinical Center Detailed Web Page</description>
    </link>
    <verification_date>August 22, 2023</verification_date>
    <study_first_submitted>August 17, 2023</study_first_submitted>
    <study_first_submitted_qc>August 17, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 21, 2023</study_first_posted>
    <last_update_submitted>August 28, 2023</last_update_submitted>
    <last_update_submitted_qc>August 28, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">August 29, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Sponsor</responsible_party_type>
    </responsible_party>
    <keyword>Hematologic toxicity</keyword>
    <keyword>Ruxolitinib</keyword>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Anemia, Aplastic</mesh_term>
      <mesh_term>Bone Marrow Failure Disorders</mesh_term>
      <mesh_term>Pancytopenia</mesh_term>
    </condition_browse>
    <patient_data>
      <sharing_ipd>No</sharing_ipd>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT05998408
  org study id: 10001667
  secondary id: 001667-H
  nct id: NCT05998408
  lead sponsor: 
  is fda regulated drug: Yes
  is fda regulated device: No
  Background:
  
        Immune bone marrow failure is a condition that occurs when a person s immune system attacks
        the cells of the bone marrow. This can lead to diseases including different types of anemias
        and blood cancers. Some of these diseases can be deadly. Better treatments are needed.
  
        Objective:
  
        To test a drug (ruxolitinib) in people with different types of immune bone marrow failure.
  
        Eligibility:
  
        Adults aged 18 and older with an immune bone marrow failure.
  
        Design:
  
        Participants will be screened. They will have a physical exam. They will give samples of
        blood and saliva. They will have a bone marrow biopsy: A large needle will be inserted into a
        small cut to remove a sample of the soft tissue inside the bone. Some participants may have a
        skin biopsy: A small piece of skin will be removed. Some may have a computed tomography (CT)
        scan: They will lie on a table that slides into a donut-shaped machine that uses X-rays to
        make pictures of the inside of the body.
  
        Ruxolitinib is a tablet taken by mouth. Participants will take the drug twice a day for up to
        6 months.
  
        Participants will have blood tests every week while they are taking the drug. These tests can
        be done by the participant s own physician and the results sent to the researchers.
  
        Participants will have clinic visits after taking the drug for 3 months and 6 months and then
        after 1, 2, and 3 years. The blood tests and bone marrow biopsy will be repeated.
  
        Participants who improve while taking the drugs may go on to an extension phase of the study.
  Study description:
  
        This is a prospective, non-randomized, phase I/II study in which participants with
        relapsed/refractory immune marrow failure (severe aplastic anemia, moderate aplastic anemia,
        single lineage cytopenias, T-LGL, and hypoplastic MDS) will be treated with the JAK1/2
        inhibitor ruxolitinib. Our hypothesis is that JAK1/2 inhibition with ruxolitinib will result
        in hematologic improvement in participants with immune marrow failure.
  
        Objectives:
  
        The primary objectives are to assess safety and efficacy of the JAK1/2 inhibitor ruxolitinib
        in immune marrow failure.
  
        The secondary objectives are to assess early and long-term hematologic response, depth of
        response, development of transfusion independence, rate of relapse, rate of clonal evolution
        to myeloid malignancy and Paroxysmal Nocturnal Hemoglobinuria (PNH), 3-year overall survival,
        response after re-initiation of therapy in relapsed participants, maximum tolerated dose.
  
        Endpoints:
  
        The primary endpoints are: (a) the primary safety endpoint will be number of participants who
        complete a full course of ruxolitinib without cessation required by hematologic toxicity in
        the 6 months following treatment initiation; (b) The primary efficacy endpoint is overall
        response (OR) rate by 6 months.
  
        The secondary endpoints are time to OR, OR at 3 months, development of transfusion
        independence at 3 and 6 months, type of response at 3 and 6 months, rate of relapse up to 3
        years, rate of clonal evolution up to 3 years, 3-year overall survival (OS), and number of
        participants tolerating maximum ruxolitinib dose.
  allocation: Non-Randomized
  intervention model: Single Group Assignment
  primary purpose: Treatment
  masking: None (Open Label)
  measure: The number of patients who complete a full course of ruxolitinib without cessation is required by hematologic toxicity.
  time frame: 6 months
  description: The primary safety endpoint will be the number of patients who complete a full course of ruxolitinib without cessation required by hematologic toxicity in the 6 months following treatment initiation.
  measure: Overall Response Rate. Patients who develop a Complete response at 3 months and stop the drug will also be deemed responders even if they subsequently relapse.
  time frame: 6 months
  description: The primary efficacy endpoint is the OR rate by 6 months. Patients who develop CR at 3 months and stop the drug will also be deemed responders even if they subsequently relapse.
  measure: Hematological response
  time frame: 3, 12 months, and yearly thereafter
  measure: Depth of response
  time frame: 3, 6 months
  measure: Rate of clonal evolution
  time frame: Variable
  measure: Rate of relapse
  time frame: Variable
  measure: Time to transfusion independence
  time frame: Variable
  measure: Overall survival
  time frame: Variable
  measure: Hematological response of relapse subjects that re-start treatment
  time frame: Variable
  measure: Percent of patients tolerating 20 mg ruxolitinib BID.
  time frame: Variable
  arm group label: Subjects with hypoplastic MDS
  arm group type: Experimental
  description: Subjects are defined as patients with a diagnosis of hMDS clinically confirmed by a licensed physician or an advanced practitioner who meets the inclusion and exclusion criteria and can provide informed consent.
  arm group label: Subjects with MAA
  arm group type: Experimental
  description: Subjects are defined as patients with a diagnosis of MAA clinically confirmed by a licensed physician or an advanced practitioner who meets the inclusion andexclusion criteria and can provide informed consent.
  arm group label: Subjects with PRCA
  arm group type: Experimental
  description: Subjects are defined as patients with a diagnosis of PRCA clinically confirmed by a licensed physician or advanced practitioners who meet the inclusion and exclusion criteria and can provide informed consent.
  arm group label: Subjects with SAA
  arm group type: Experimental
  description: Subjects are defined as patients with a diagnosis of SAA clinically confirmed by a licensed physician oran advanced practitioner who meets the inclusion andexclusion criteria and can provide informed consent.
  arm group label: Subjects with TLGL
  arm group type: Experimental
  description: Subjects are defined as patients with a diagnosis of TLGL clinically confirmed by a licensed physician or advanced practitioner who meets the inclusion and exclusion criteria and can provide informed consent.
  intervention type: Drug
  intervention name: Ruxolitinib
  description: Subjects will be instructed to take ruxolitinib at up to 20mg (total) BID for up to 6 months (with or without food)
  arm group label: Subjects with MAA
  arm group label: Subjects with PRCA
  arm group label: Subjects with SAA
  arm group label: Subjects with TLGL
  arm group label: Subjects with hypoplastic MDS
  criteria: 
  gender: All
  minimum age: 18 Years
  maximum age: 99 Years
  healthy volunteers: No
  last name: Emma M Groarke, M.D.
  role: Principal Investigator
  affiliation: National Heart, Lung, and Blood Institute (NHLBI)
  last name: Ivana Darden, R.N.
  phone: (301) 827-2988
  email: ivana.darden@nih.gov
  last name: Emma M Groarke, M.D.
  phone: (301) 496-5093
  email: emma.groarke@nih.gov
  facility: 
  contact: 
  country: United States
  url: https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_001667-H.html
  description: NIH Clinical Center Detailed Web Page
  responsible party type: Sponsor
  mesh term: Anemia, Aplastic
  mesh term: Bone Marrow Failure Disorders
  mesh term: Pancytopenia
  sharing ipd: No